HORIZON EUROPE
Europeo
Scope:Specific challenge: Vaccines offer a safe and cost-effective way to protect large populations against infectious diseases, or at least to mitigate the clinical course of these diseases. Furthermore, they may in combination with other treatment modalities contribute to an eradicative cure for HIV. Many poverty-related and neglected infectious diseases however continue to escape attempts to develop effective vaccines against them.
Disappointing results of recent clinical trials point to bottlenecks in identifying viable candidate vaccines, which if unaddressed will continue to present significant risks of failure at relatively late stages of the development process.
The specific challenge will be to shift this ‘risk curve’ in order to better select successful vaccine candidates (and discard those with a higher risk of failure) at an earlier stage of the vaccine development process, for preventive as well as therapeutic vaccines.
Scope: Proposals should focus on strengthening the capacity for discovery and early development of new vaccine candidates for HIV/AIDS by addressing all of the following inter-related elements:
1....
ver más
Scope:Specific challenge: Vaccines offer a safe and cost-effective way to protect large populations against infectious diseases, or at least to mitigate the clinical course of these diseases. Furthermore, they may in combination with other treatment modalities contribute to an eradicative cure for HIV. Many poverty-related and neglected infectious diseases however continue to escape attempts to develop effective vaccines against them.
Disappointing results of recent clinical trials point to bottlenecks in identifying viable candidate vaccines, which if unaddressed will continue to present significant risks of failure at relatively late stages of the development process.
The specific challenge will be to shift this ‘risk curve’ in order to better select successful vaccine candidates (and discard those with a higher risk of failure) at an earlier stage of the vaccine development process, for preventive as well as therapeutic vaccines.
Scope: Proposals should focus on strengthening the capacity for discovery and early development of new vaccine candidates for HIV/AIDS by addressing all of the following inter-related elements:
1. Establishment of a platform for the discovery and selection of several new diverse and novel preventive or therapeutic vaccine candidates for HIV/AIDS, and their pre-clinical and early clinical testing.
2. The major bottlenecks in vaccine development should be addressed; in particular better ways for early distinction between successful candidates and those that will eventually fail in late stage clinical trials. Proposals should therefore pool expertise in the areas of in vitro and in silico testing, predictive animal models, predictive correlates of protection, phase 0 trials, first in man trials and innovative risk prediction methods, taking into account sex-specific differences. Based on these criteria the most promising new vaccine candidates for HIV/AIDS will be compared and selected in an objective and transparent process according to their merit.
3. The successful proposal shall continue its vaccine development in the context of the European and Developing Countries Clinical Trials Partnership (EDCTP), and a pathway and commitment towards this direction must form an integral part of the proposal. It shall also ensure collaboration with other EU-funded research actions in related research fields.
In line with the Union’s strategy on international cooperation[1] in research and innovation, international cooperation is encouraged. The proposals should also address the barriers and possible facilitators regarding the uptake and implementation of a new vaccine in low, middle and high income countries in different regions of the world.
The Commission considers that proposals requesting a contribution from the EU of between 15 and 20 million euro would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected impact: This should provide:
Reduction in the cost associated with late stage preventive or therapeutic vaccine failure, increasing the number of other candidates which can be tested with the same resources, thus increasing the chance of discovery of an effective vaccine Establishment of close links with the European and Developing Countries Clinical Trials Partnership (EDCTP), for the further clinical development of the vaccine candidates identified in the present initiative. Type of action: Research and innovation actions
[1] COM(2012)497
Cross-cutting Priorities:International cooperationGender
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
The budget breakdown for this call is given in the call conditions section of the work programme. [,ADD hyprelink]:
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under all topics in calls under the Societal Challenge ‘Health, demographic change and well-being’.
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
Evaluation
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme with the following exceptions:
- The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.
- If a proposal fails to achieve the threshold for a criterion at any stage, the evaluation of the proposal will be stopped.
- For the evaluation of topics PHC9 – 2015, the Commission will organise hearings at stage 1 with applicants as part of the panel d... Please read carefully all provisions below before the preparation of your application.
The budget breakdown for this call is given in the call conditions section of the work programme. [,ADD hyprelink]:
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under all topics in calls under the Societal Challenge ‘Health, demographic change and well-being’.
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
Evaluation
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme with the following exceptions:
- The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.
- If a proposal fails to achieve the threshold for a criterion at any stage, the evaluation of the proposal will be stopped.
- For the evaluation of topics PHC9 – 2015, the Commission will organise hearings at stage 1 with applicants as part of the panel deliberations for all proposals above threshold.
3.2 Guide to the submission and evaluation process
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template (administrative forms and structure of technical annex)
Annotated Model Grant Agreement
For information, a pdf. template of the evaluation form for this topic is available on the call page under call documents.
Additional provisions:
Horizon 2020 budget flexibility
Classified information
Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta